The AJMC® Biosimilars compendium is a comprehensive resource for news and expert insights into these biological products, including clinical research, patent and legal news, and regulatory updates.
Dr Sonia Oskouei on Managed Care’s Impact After Rollout of Adalimumab BiosimilarsMay 16th 2022
While 2023 is a big year with at least 7 adalimumab biosimilars expected to come to market, 2024 will be even more important because all the products will be on the market and formulary decisions can be made, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health.
Managed Care Has a Key Role in Biosimilar Adoption, Says Cardinal's OskoueiMay 12th 2022
Biosimilar adoption can be accelerated or stymied depending on actions taken by the managed care space, explained Sonia Oskouei, PharmD, vice president, biosimilars, Cardinal Health, during a session at Asembia’s Specialty Pharmacy Summit.
Dr Gillian Woollett Highlights International Markets With Successful Biosimilar AdoptionApril 29th 2022
Gillian Woollett, MA, Dphil, vice president and head of regulatory strategy and policy at Samsung Bioepis, gives insight into what international markets the United States could look to as examples of good biosimilar adoption.
Ryan Haumschild, PharmD, Explains How Emory Healthcare Will Address the Influx of Humira Biosimilars in 2023April 23rd 2022
Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and Winship Cancer Institute, gives insight into how his practice will handle the influx of at least 7 adalimumab biosimilars referencing Humira that are expected to enter the market in 2023.
Equivalent Safety, Efficacy Between Herceptin and Trastuzumab Biosimilar for Gastric CancerApril 7th 2022
A trastuzumab biosimilar was found to have similar safety and efficacy with the reference product (Herceptin) in patients with advanced gastric cancer, a population previously excluded from bioequivalence studies for trastuzumab biosimilars.
Dr Chelsee Jensen on the Solution to Stocking Multiple Biosimilars for the Same Reference ProductApril 7th 2022
Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, provides her take on why practices will have to continue to stock multiple biosimilars for the same reference product.
What Can Payers Do to Improve Biosimilar Uptake? Ryan Haumschild, PharmD, Weighs InApril 2nd 2022
Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, explains how payers can play an essential role in improving biosimilar adoption.
Infliximab Biosimilar Maintains Outcomes, Remission Status After Switch From OriginatorMarch 24th 2022
Patients switched from the originator product maintained their clinical outcomes and remissions status while biologic-naïve patients recorded positive responses and remission outcomes after initiating infliximab-dyyb.
Panel on Prior Authorization Reveals Role PBMs Play in Biosimilar Uptake in OncologyMarch 22nd 2022
During the recent Association of Community Cancer Centers’ 2022 Annual Meeting & Cancer Center Business Summit, panelists suggested that the laser focus on rebates by pharmacy benefit managers (PBMs) may be hindering uptake of biosimilars, thereby keeping some off of formulary lists.
Julie Reed Previews 2022: The Year of Expanded Access to BiosimilarsMarch 14th 2022
As the United States awaits market introduction for adalimumab biosimilars in 2023, 2022 is going to be the year of expanding access to biosimilars, according to Julie M. Reed, the new executive director of the Biosimilars Forum.
The Biosimilars Forum's Julie Reed Predicts How Interchangeability Will Impact Biosimilar UptakeFebruary 25th 2022
Julie M. Reed, the new executive director of the Biosimilars Forum, offers her opinion on how interchangeability will impact US biosimilar uptake now that the FDA has given the designation to 2 biosimilars.
CMS Official Cites OCM as Example of Biosimilar SuccessFebruary 21st 2022
Purva Rawal, PhD, senior advisor and chief strategy officer, Center for Medicare and Medicaid Innovation, addressed attendees at the Association for Accessible Medicines' Access! annual meeting, held in Orlando, Florida, February 15-16.
Biosimilars Available for 3 Drugs Costing More Through Hospitals, PhysiciansFebruary 16th 2022
AHIP released a report looking at the price markups for 10 drugs that can be delivered more affordably through specialty pharmacies, including 3 drugs with multiple biosimilars available.
A Review of Biosimilars in 2021: Regulatory, Legal Developments, and What’s in Store for the New YearFebruary 14th 2022
Although the COVID-19 pandemic has led to mass slowdowns in drug approvals and biosimilar launches, 2021 signaled a stronger focus on biosimilars going forward, with new regulatory bills and a crackdown on anticompetitive practices.
VA Study: Patients Switching to Biosimilar Infliximab More Likely to Stop TreatmentFebruary 11th 2022
Physician and patient resistance to switching from an innovator or reference product to a biosimilar—or from one biosimilar to another—constitutes one of the major barriers to biosimilar adoption, despite the cost savings that can be achieved.
Real-world Usage of Bevacizumab-bvzr Biosimilar in US Oncology Practice
Real-world adoption of bevacizumab-bvzr biosimilar was retrospectively assessed, revealing switching between biosimilars and the reference product and utilization in extrapolated indications and combination regimens.